{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:12:13Z","timestamp":1789924333811,"version":"4.0.1"},"reference-count":25,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Multiple sclerosis (MS) negatively affects health-related quality of life (HRQoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate HRQoL in people with highly active relapsing MS treated with cladribine tablets (CladT; 3.5 mg\/kg cumulative dose over 2 years) in CLARIFY-MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Changes in the MS quality of life (MSQoL)-54 scores were analysed using a repeated mixed-effects linear model. Subgroup analyses were performed for participants who were pretreatment-na\u00efve and those pretreated with disease-modifying therapies (DMTs) before initiating CladT. Safety and tolerability of CladT were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>MSQoL-54 physical (mean change = 4.86; 95% confidence interval (CI) = 3.18, 6.53) and mental health (4.80; 95% CI = 3.13, 6.46) composite scores (primary endpoints) showed significant improvement at Month 24 versus Baseline ( p &lt; 0.0001). Changes in the MSQoL-54 scores were consistent across the pretreatment-na\u00efve and DMT-pretreated subgroups. No new severe or opportunistic infections occurred. Most post-baseline lymphopenia events were Grade 1\u20132 in severity. Transient Grade-3 lymphopenia was observed in 19.7% (95\/482) of participants. Grade-4 lymphopenia was not observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CladT treatment significantly improved the mean MSQoL-54 physical and mental health composite scores over 2 years. CladT efficacy in HRQoL, relapse rates and Expanded Disability Status Scale scores demonstrates its multidimensional effects in MS treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585231205962","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T04:53:16Z","timestamp":1700283196000},"page":"1808-1818","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-2796","authenticated-orcid":false,"given":"Bruno","family":"Brochet","sequence":"first","affiliation":[{"name":"INSERM U 1215, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-7579","authenticated-orcid":false,"given":"Alessandra","family":"Solari","sequence":"additional","affiliation":[{"name":"Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[{"name":"University of Newcastle, Newcastle, NSW, Australia\/Division of Neurology, John Hunter Hospital, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-5219","authenticated-orcid":false,"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Langdon","sequence":"additional","affiliation":[{"name":"Department of Psychology, Royal Holloway, University of London, Egham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Hupperts","sequence":"additional","affiliation":[{"name":"Zuyderland Medisch Centrum Sittard, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Selmaj","sequence":"additional","affiliation":[{"name":"Center for Neurology, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, and Azienda Ospedaliero Universitaria Policlinico \u201cG. Rodolico\u201d \u2013 San Marco, University of Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Brieva","sequence":"additional","affiliation":[{"name":"IRBlLeida, Hospital Arnau de Vilanova, L\u00e9rida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Maida","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nektaria","family":"Alexandri","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Smyk","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nolting","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Keller","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology Centre of Multiple Sclerosis of Catalonia (Cemcat), University Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kubala Havrdova","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"key":"bibr1-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.039"},{"key":"bibr2-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002564"},{"key":"bibr3-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1532-1"},{"key":"bibr4-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"bibr5-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"bibr6-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70005-5"},{"key":"bibr7-13524585231205962","unstructured":"MAVENCLAD\u00ae (Cladribine tablets; summary of product characteristics). Amsterdam: Merck Europe B.V, 2022."},{"key":"bibr8-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"bibr9-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726380"},{"key":"bibr10-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103385"},{"key":"bibr11-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0444-x"},{"key":"bibr12-13524585231205962","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (2017, accessed 8 September 2023)."},{"key":"bibr13-13524585231205962","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK338448\/ (2018, accessed 8 September 2023)."},{"key":"bibr14-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1111\/jep.13321"},{"key":"bibr15-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101944"},{"key":"bibr16-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0220-1"},{"key":"bibr17-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2014.06.005"},{"key":"bibr18-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516677589"},{"key":"bibr19-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"bibr20-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2014.894462"},{"key":"bibr21-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.9"},{"key":"bibr22-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.06.004"},{"key":"bibr23-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C"},{"key":"bibr24-13524585231205962","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616634247"},{"key":"bibr25-13524585231205962","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S248272"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231205962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585231205962","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231205962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:13:26Z","timestamp":1777695206000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585231205962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":25,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1177\/13524585231205962"],"URL":"https:\/\/doi.org\/10.1177\/13524585231205962","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]}}}